Trabedersen
As of the edition of 20 October 2026, Trabedersen is an oligonucleotide: stopped in 2023; acts on TGFB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Oligonucleotide
- Registered trials
- 4, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Infections; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Trabedersen.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TGFB2 | Transforming growth factor beta-2 proprotein | P61812 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 0 | 1 | 1 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Isarna Therapeutics | Lead sponsor of trials | 2008 to now |
| Oncotelic | Lead sponsor of trials | 2021 to now |